No decline in GI cotherapy or healthcare costs with switch to COX-2 selective drugs

Switching from traditional nonsteroidal anti-inflammatory drugs (NSAIDs) to COX-2 selective drugs does not result in a decrease in gastrointestinal (GI) medical cotherapy. Furthermore, there is no reduction in GI healthcare costs when patients are switched from NSAIDs to selective COX-2 inhibitors, said Loren Laine, MD, at Digestive Disease Week in San Francisco.